Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct;26(5):723-744.
doi: 10.1007/s11154-025-09941-0. Epub 2025 Jan 21.

Poor muscle quality: A hidden and detrimental health condition in obesity

Affiliations
Review

Poor muscle quality: A hidden and detrimental health condition in obesity

Flavio T Vieira et al. Rev Endocr Metab Disord. 2025 Oct.

Abstract

Poor muscle quality (MQ) is a hidden health condition in obesity, commonly disregarded and underdiagnosed, associated with poor health-related outcomes. This narrative review provides an in-depth exploration of MQ in obesity, including definitions, available assessment methods and challenges, pathophysiology, association with health outcomes, and potential interventions. MQ is a broad term that can include imaging, histological, functional, or metabolic assessments, evaluating beyond muscle quantity. MQ assessment is highly heterogeneous and requires further standardization. Common definitions of MQ include 1) muscle-specific strength (or functional MQ), the ratio between muscle strength and muscle quantity, and 2) muscle composition (or morphological MQ), mainly evaluating muscle fat infiltration. An individual with obesity might still have normal or higher muscle quantity despite having poor MQ, and techniques for direct measurements are needed. However, the use of body composition and physical function assessments is still limited in clinical practice. Thus, more accessible techniques for assessing strength, muscle mass, and composition should be further explored. Obesity leads to adipocyte dysfunction, generating a low-grade chronic inflammatory state, which leads to mitochondrial dysfunction. Adipocyte and mitochondrial dysfunction result in metabolic dysfunction manifesting clinically as insulin resistance, dyslipidemia, and fat infiltration into organs such as muscle, which in excess is termed myosteatosis. Myosteatosis decreases muscle cell function and insulin sensitivity, creating a vicious cycle of inflammation and metabolic derangements. Myosteatosis increases the risk of poor muscle function, systemic metabolic complications, and mortality, presenting prognostic potential. Interventions shown to improve MQ include nutrition, physical activity/exercise, pharmacology, and metabolic and bariatric surgery.

Keywords: Fat infiltration; Muscle mass; Muscle quality; Muscle strength; Myosteatosis; Obesity.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: All authors declare no competing interests with this manuscript. MCG has received honoraria and/or paid consultancy from Abbott Nutrition, Nutricia, and Nestlé Health Science Brazil. BHG has received speaking honorarium from Baxter Corporation. CMP has received honoraria and/or paid consultancy from Abbott Nutrition, Nutricia, Nestle Health Science, Pfizer, Amra Medical, Novo Nordisk, and funding from Almased for unrelated research. AMH is on advisory boards for Rhythm Pharmaceuticals, Novo Nordisk Canada, and Pfizer Canada. She is a clinical trial investigator for Rhythm Pharmaceuticals, Levo Therapeutics, Acadia Pharmaceuticals, Novo Nordisk and Eli Lilly. The remaining authors have no competing interest to declare.

References

    1. World Health Organization. Obesity and overweight. 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight . Accessed June 1.
    1. Lingvay I, Cohen VR, Roux LWC, Sumithran P. Obesity in adults. The Lancet. 2024;404:972–87. https://doi.org/10.1016/S0140-6736(24)01210-8 . - DOI
    1. Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr. 2022;41:990–1000. https://doi.org/10.1016/j.clnu.2021.11.014 . - DOI - PubMed
    1. Donini LM, Busetto L, Bischoff SC, Cederholm T, Ballesteros-Pomar MD, Batsis JA, et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts. 2022;15:321–35. https://doi.org/10.1159/000521241 . - DOI - PubMed - PMC
    1. Gortan Cappellari G, Guillet C, Poggiogalle E, Ballesteros Pomar MD, Batsis JA, Boirie Y, et al. Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) – proceedings from the SOGLI consortium meeting in Rome November 2022. Clin Nutr. 2023;42:687–99. https://doi.org/10.1016/j.clnu.2023.02.018 . - DOI - PubMed

MeSH terms

LinkOut - more resources